secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0000950170-23-050995
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics posts R&D Day corporate presentation; no financial or clinical updates
--------------------------------------------------------------------------------

- Presentation posted Oct 2, 2023, on Ovid investor relations website.
- Slide titled 'Dawn of the neurotherapeutics era' by CEO Dr. Jeremy Levin.
- Filing exhibit includes only the cover slide; no detailed data disclosed.
- No material news regarding pipeline, financials, or guidance in this 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023050995/0000950170-23-050995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023050995/ovid-20231002.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-050995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer